Skip to main content

Improving the production of the micafungin precursor FR901379 in an industrial production strain



Micafungin is an echinocandin-type antifungal agent used for the clinical treatment of invasive fungal infections. It is semisynthesized from the sulfonated lipohexapeptide FR901379, a nonribosomal peptide produced by the filamentous fungus Coleophoma empetri. However, the low fermentation efficiency of FR901379 increases the cost of micafungin production and hinders its widespread clinical application.


Here, a highly efficient FR901379-producing strain was constructed via systems metabolic engineering in C. empetri MEFC09. First, the biosynthesis pathway of FR901379 was optimized by overexpressing the rate-limiting enzymes cytochrome P450 McfF and McfH, which successfully eliminated the accumulation of unwanted byproducts and increased the production of FR901379. Then, the functions of putative self-resistance genes encoding β-1,3-glucan synthase were evaluated in vivo. The deletion of CEfks1 affected growth and resulted in more spherical cells. Additionally, the transcriptional activator McfJ for the regulation of FR901379 biosynthesis was identified and applied in metabolic engineering. Overexpressing mcfJ markedly increased the production of FR901379 from 0.3 g/L to 1.3 g/L. Finally, the engineered strain coexpressing mcfJ, mcfF, and mcfH was constructed for additive effects, and the FR901379 titer reached 4.0 g/L under fed-batch conditions in a 5 L bioreactor.


This study represents a significant improvement for the production of FR901379 and provides guidance for the establishment of efficient fungal cell factories for other echinocandins.


Echinocandin-type antifungal agents are semisynthesized from lipohexapeptides, nonribosomal peptides produced by filamentous fungi [1, 2]. As an inhibitor of β-1,3-glucan synthase, echinocandins can potently inhibit the growth of fungal pathogens by blocking the biosynthesis of β-1,3-glucan, which is a predominant and specific constituent of the cell wall in most fungi [1, 3]. Therefore, they exhibit pronounced activity against a broad range of Candida spp. and Asperillus spp., especially against azole-resistant strains [4,5,6,7]. To date, caspofungin, micafungin, and anidulafungin have been used as first-line drugs to treat invasive fungal infections [3, 6, 8, 9]. Unlike other echinocandin-type agents, micafungin exhibits excellent water solubility due to the sulfonate moiety originating from the precursor FR901379 [10, 11]. The high water solubility significantly improves the pharmacological efficacy and pharmacokinetic properties [12].

Industrial production of micafungin includes three steps: FR901379 is produced through Coleophoma empetri fermentation [11], then the palmitic acid side chain of FR901379 is deacylated and substituted with the optimized N-acyl side chain (Fig. 1) [13, 14]. The production of FR901379 is the key step in the manufacture of micafungin. However, the low titer, byproducts with similar structures, and poor mycelium pellet are obstacles to high yield during C. empetri cultivation, which increases the production cost and complicates large-scale purification processes [11, 15]. Although mutation breeding and fermentation optimization have been applied to improve the production of FR901379, the above problems remain unsolved [15, 16].

Fig. 1
figure 1

The industrial production process of micafungin and biosynthetic gene clusters of FR901379

Metabolic engineering provides promising strategies to improve the production of natural products, such as enhancing and optimizing the biosynthesis pathway [17,18,19], eliminating the competitive pathway [18, 20, 21], and engineering energy homeostasis [22, 23]. Several strategies have been successfully applied to improve the production of echinocandins. By disrupting the key gene for the synthesis of the amino acid building block, the production of the byproduct pneumocandin A0 was abolished in the pneumocandin B0-producing strain Glarea lozoyensis ATCC 20868 [24]. By replacing the proline hydroxylase gloF of G. lozoyensis SIPI1208 with ap-htyE from an echinocandin B-producing strain, the mutants abolished the production of pneumocandin C0 and showed an increased titer of pneumocandin B0 [25]. For the production of anidulafungin precursor echinocandin B, Min et al. increased the titer of echinocandin B in Aspergillus delacroxii SIPIW15 by blocking the biosynthetic pathway of sterigmatocystin [20]. However, there is no report on the metabolic engineering of the FR901379-producing strain because of the absence of a detailed biosynthetic mechanism.

Recently, the biosynthetic pathway of FR901379 in C. empetri has been elucidated by gene deletion, enzymatic assays, and heterologous refactoring [26, 27]. The involved biosynthetic genes are distributed in two separate biosynthetic gene clusters (BGCs), the core biosynthetic gene cluster mcf and the O-sulfonation gene cluster (Fig. 1). The biosynthesis of FR901379 can be divided into three parts: the synthesis of nonproteinogenic amino acids, the assembly of palmitic acid and six building blocks, and the post-modification of cyclized lipohexapeptide. This research progress sheds light on metabolic engineering to improve the production of FR901379 and reduce the accumulation of byproducts. Here, systems metabolic engineering strategies were developed for the FR901379-producing strain C. empetri MEFC09, including optimization of the biosynthesis pathway, overexpression of the transcriptional activator, and engineering of self-resistance genes. A more efficient cell factory with a higher FR901379 titer and fewer byproducts was obtained.

Results and discussion

Production of FR901379 in C. empetri MEFC09

The production capacity of FR901379 of the C. empetri MEFC09 parental strain was evaluated in a shake flask. The titer of FR901379 was approximately 300 mg/L when cultured for 10 days, which is still relatively low for industrial manufacture (Fig. 2A). More critically, two analogues accumulated together with the target product, 20% WF11899B (Compound 2) and 8% WF11899C (Compound 3, Fig. 2B), which greatly complicate the large-scale purification of FR901379 during the manufacturing of micafungin [11]. The structural differences between FR901379 and these two analogues are the hydroxyl groups located on L-ornithine and 3S-hydroxyl-3'-O-sulfonate-homotyrosine (Fig. 2C). Recently, we elucidated the biosynthesis pathway of FR901379, which showed that WF11899B and WF11899C are intermediates prior to hydroxylation in the biosynthesis of FR901379 [27]. The hydroxylations of L-ornithine are catalyzed by the cytochrome P450 (CYP) enzyme McfH and hydroxylation of 3S-hydroxyl-3'-O-sulfonate-homotyrosine is catalyzed by the CYP enzyme McfF (Fig. 2C). Therefore, the accumulation of WF11899B and WF11899C might be due to insufficient modification catalyzed by McfH and McfF.

Fig. 2
figure 2

FR901379 production in wild-type C. empetri MEFC09. A Time course of FR901379 production in C. empetri MEFC09. B High performance liquid chromatography (HPLC) profile of the extract from C. empetri MEFC09; 1: FR901379; 2: WF11899B; 3: WF11899C. C The relationship between Compounds 1, 2, and 3

Optimization of the rate-limiting processes

To reduce the byproducts (WF11899B and WF11899C) and increase the production of FR901379, the key genes mcfF and mcfH were overexpressed in C. empetri MEFC09 using the promoter of glyceraldehyde-3-phosphate dehydrogenase gene (PgpdAt), generating the mutant strains MEFC09-F and MEFC09-H, respectively (Fig. 3A). Because the overexpression cassettes were integrated into the chromosome by random insertion, ten transformants of each construct were randomly selected for shake-flask fermentation evaluation. The ratio of WF11899B was significantly decreased in all transformants of MEFC09-F (Fig. 3B, C). The titers of FR901379 were significantly increased in six transformants. The titer of FR901379 reached 706 mg/L in the best transformant MEFC09-F-1, which was 130% higher than that of C. empetri MEFC09 (Fig. 3C). On the other hand, the production of WF11899C was almost eliminated in all transformants of MEFC09-H (Fig. 3B, D). Meanwhile, the titers of FR901379 and WF11899B were both increased to varying degrees (Fig. 3D). These results indicate that the reactions catalyzed by McfF and McfH are indeed the rate-limiting steps in the production of FR901379. In addition, the O-sulfonation genes mcfP and mcfS are also overexpressed in C. empetri MEFC09. However, there was no significant difference in the production of FR901379 and other analogues, suggesting that O-sulfonation may not be a rate-limiting step in the biosynthesis of FR901379 in C. empetri MEFC09 (Additional file 1: Fig. S2).

Fig. 3
figure 3

Reducing byproducts through overexpression of mcfF and mcfH encoding the rate-limiting enzymes. A Schematic diagrams of the overexpression of mcfF and mcfH. B HPLC profiles of extracts from MEFC09-F, MEFC09-H, and MEFC09. Titers of FR901379, WF11899B, and WF11899C in the mutant strains of MEFC09-F (C) and MEFC09-H (D) were quantified; WT: parental strain C. empetri MEFC09; F: mutant strains MEFC09-F; H: mutant strains MEFC09-H. Statistical analysis was performed by using Student’s t test (**p < 0.01)

To further eliminate WF11899B and WF11899C simultaneously, the expression cassette PgpdAt-mcfF-Tpgk-neo was introduced into MEFC09-H-6 to reduce the accumulated WF11899B. Nine MEFC09-HF transformants coexpressing mcfH and mcfF were tested for the production of FR901379, WF11899B, and WF11899C. The results were more complex and variable than overexpressing a single gene because of the random integration of target genes and the incongruity of hydroxylations. In transformants MEFC09-HF-7 and MEFC09-HF-8, the titer of WF11899B was significantly increased and much higher than that of FR901379. This might be due to the imbalance between McfF and McfH caused by the uncertainty of integration sites and copies of expression cassettes [26, 28]. In other transformants, the titers of FR901379 were improved significantly compared to the parental strains MEFC09-H-6 and MEFC09, while the proportions of WF11899B and WF11899C were both reduced (Fig. 4B). In the best mutant MEFC09-HF-5, only very small amounts of WF11899B and WF11899C were detected, and the titer of FR901379 was increased from 284 mg/L to 572 mg/L (Fig. 4A, B). Therefore, an engineered FR901379-producing strain with higher yield and fewer byproducts was constructed by optimizing the rate-limiting steps of FR901379 biosynthesis.

Fig. 4
figure 4

Combinational overexpression of mcfF and mcfH. A HPLC profiles of extracts from strains MEFC09-HF, MEFC09-H, and MEFC09. B Titers of FR901379, WF11899B, and WF11899C were quantified in MEFC09-HF; HF: mutant strains MEFC09-HF; H: mutant strains MEFC09-H; WT: parental strain C. empetri MEFC09.

Functional evaluation of the potential self-resistance genes

Self-resistance plays an important role in the efficient production of secondary metabolites because of the toxic effects of metabolites on its producer [29]. Malla et al. overexpressed the resistance gene drrC in the doxorubicin-producing strain Streptomyces peucetius ATCC 27952, and the titer of doxorubicin in the mutant strain was 5.1-fold higher than that of the parental strain [30]. β-1,3-glucan synthase is the inhibitory target of echinocandins, indicating that the β-1,3-glucan synthase-encoding gene is a self-resistance gene for echinocandin-producing strains [1]. Yue et al. discovered two β-1,3-glucan synthase coding genes (prfks1n and prfks1a) in the echinocandin-producing fungus P. radicicola NRRL 12192. Prfks1n is essential for cell wall formation and prfks1a mainly contributes to protection from echinocandin toxicity [31]. Here, two putative β-1,3-glucan synthase coding genes were also found in the genome of C. empetri MEFC09 by BLAST analysis. Gene CEfks1 (11087_g) showed 76% identity to prfks1n, while CEfks2 (11230_g) showed 86% identity to prfks1a (Fig. 5A). Transcriptome analysis results demonstrated that CEfks1 exhibited high profiles under both high and low FR901379-producing conditions, whereas CEfks2 only exhibited a high profile under high FR901379-producing conditions (Fig. 5A). Thus, we hypothesize that CEfks1 is the housekeeping gene responsible for the formation of the cell wall and that CEfks2 contributes to self-resistance to FR901379.

Fig. 5
figure 5

Functional verification of self-resistance genes related to FR901379. A The transcription levels and homologous genes of the genes CEfks1 and CEfks2; MKF: FR901379 high-producing condition; LPM: FR901379 low-producing condition; FPKM: Fragments Per Kilobase of exon model per Million mapped fragments. B Schematic diagram for the construction of CEfks1 and CEfks2 disruption mutants. C FR901379 titers were quantified in the CEfks disruption strains and CEfks2 overexpression strains; WT: C. empetri MEFC09; ∆fks1: MEFC09-∆CEfks1; ∆fks2: MEFC09-∆CEfks2; OEfks2: MEFC09::CEfks2. D Images of mycelial morphology of the CEfks1 and CEfks2 disruption strains; PDA: the strains were grown on PDA medium; SM: stereo microscope images (8 × objective lens) of mycelia of the cultivation broth, all scale bars represent 2 mm; SEM: scanning electron microscopic images of CEfks disruption strains

To verify the effect of CEfks1 and CEfks2 on the production of FR901379, these two genes were individually disrupted in C. empetri MEFC09 (Fig. 5B). The double-knockout strain could not be obtained. ∆CEfks1 and ∆CEfks2 exhibited different growth rates, pellet formation, and cell wall structures (Fig. 5). Deleting CEfks1 significantly decreased the growth rate on potato dextrose agar (PDA) plates, whereas the colony of ∆CEfks2 was larger and fluffier than that of C. empetri MEFC09 (Fig. 5D). The FR901379 titer of ∆CEfks1 was 30% higher than that of C. empetri MEFC09, which might be caused by improved mycelial morphogenesis (Fig. 5C). The mycelia pellets of ∆CEfks1 were smaller and more regular than those of MEFC09. However, no obvious change was observed in the strain ∆CEfks2 (Fig. 5D). Further scanning electron microscopy (SEM) imaging revealed that the structure of the cell wall changed remarkably in both mutant strains ∆CEfks1 and ∆CEfks2. These results demonstrated that these genes both contribute to cell wall formation and affect the morphogenesis and growth of C. empetri.

To improve the production of FR901379 by enhancing product resistance, the putative self-resistance gene CEfks2 was overexpressed in C. empetri MEFC09. However, the titer of FR901379 was decreased and accompanied by a slight slowdown in growth (Fig. 5C). This result indicated that the resistance of C. empetri MEFC09 to FR901379 was sufficient to protect it from the current concentration of FR901379. Enhancing product resistance is not an effective strategy to improve production. Unlike resistance genes of other natural products, β-1,3-glucan synthase plays an important role in fungal cell wall formation. Genetic engineering of β-1,3-glucan synthase genes would affect morphogenesis and growth. Therefore, metabolic engineering based on self-resistance genes in echinocandin-producing strains will be more complicated and requires a strict balance between product resistance, growth, and mycelial morphology.

Improving the production of FR901379 by overexpresing the transcriptional activator McfJ

Overexpression of transcriptional activators is an effective strategy to increase the production of secondary metabolites [32, 33]. Overexpressing the specific transcriptional regulator lovE significantly improved the production of monacolin J in the industrial strain Aspergillus terreus [33]. However, the biosynthetic genes of FR901379 were distributed in two separate BGCs, including the core biosynthetic gene cluster mcf and the O-sulfonation gene cluster. The regulation of FR901379 biosynthesis is more ambiguous and complicated. The gene deletion and reverse transcription-polymerase chain reaction (RT‒PCR) results showed that mcfJ might be a transcriptional activator for the biosynthesis of FR901379 (Additional file 1: Fig. S3). The production of FR901379 was abolished completely in the mcfJ deletion mutant. It is consistent with the phenomenon observed in C. empetri SIPI1284, deleting Cehyp (homologous gene of mcfJ) broke the production of FR901379 [26]. The transcriptional levels of the FR901379 biosynthetic pathway, including the genes in the large mcf cluster and the separate O-sulfonation cluster, were significantly downregulated following mcfJ disruption (Fig. 6A, Additional file 1: Table S3).

Fig. 6
figure 6

Effects of overexpression of the transcriptional activator mcfJ on FR901379 production. A Heatmap of the mcf gene expression profile of C. empetri MEFC09, MEFC09-∆mcfJ, and MEFC09-J; WT: C. empetri MEFC09; J: mutant strains MEFC09-J. Relative expression levels are shown as a color gradient from low (blue) to high (red). B HPLC profiles of metabolites from C. empetri MEFC09 and MEFC09-J; 1: FR901379; 2: WF11899B; 3: WF11899C. C Titers of FR901379, WF11899B, and WF11899C were quantified in C. empetri MEFC09 and MEFC09-J in shake-flask cultures; J: mutant strains MEFC09-J; WT: C. empetri MEFC09. Statistical analysis was performed by using Student’s t test (***p < 0.001)

To further test the function of mcfJ and improve the production of FR901379, the expression cassette of mcfJ was constructed using the promoter PgpdAt and introduced into C. empetri MEFC09. The transformants harboring the expression cassette were confirmed by genomic PCR and designated MEFC09-J. The results of shake flask fermentation showed that all of the transformants produced significantly higher FR901379 titers than C. empetri MEFC09 (Fig. 6B, C). The highest FR901379 titer of 1.32 g/L was achieved in strain MEFC09-J-4, which was threefold higher than that in MEFC09 (Fig. 6C). In addition, the transcription levels of mcfJ and other biosynthetic genes of FR901379 were measured by RNA sequencing and were significantly increased in the mutant strain MEFC09-J (Fig. 6A, Additional file 1: Table S3). These results demonstrated that McfJ is indeed a transcriptional activator for the biosynthesis of FR901379. Although the biosynthetic genes were distributed in two separate BGCs, the production of FR901379 was coordinately regulated by McfJ. More importantly, because of this regulatory mechanism, overexpression of mcfJ was successfully developed as a very effective metabolic engineering strategy to increase the production capacity of FR901379.

Construction of a high-yield cell factory for FR901379 by combinatorial metabolic engineering

Overexpression of CYP enzymes mcfH and mcfF could significantly reduce the accumulation of byproducts, while overexpression of transcriptional activator mcfJ could remarkably increase the production of FR901379. Inspired by the performance of these two strategies, a mutant strain coexpressing mcfJ, mcfF and mcfH was constructed to achieve a superposition of beneficial effects. The expression cassettes of PgpdAt-mcfF-TtrpC and PgpdAt-mcfH-TtrpC were cointroduced into MEFC09-J-4 to generate the mutant strain MEFC09-JFH. The production of FR901379 was further improved in all engineered strains (Fig. 7A). The highest increase was observed in MEFC09-JFH-2, and the titer of FR901379 reached 2.03 g/L, which was 47% higher than that of MEFC09-J. In addition, the production of byproducts WF11899C was completely abolished in MEFC09-JFH-2, and the WF11899B ratio decreased from 14 to 4%. Therefore, a more efficient cell factory with a higher FR901379 titer and fewer byproducts was constructed by combinatorial metabolic engineering. This is the first transcriptional regulator identified in the biosynthesis of echinocandins, which will serve as a good reference for research on other echinocandins.

Fig. 7
figure 7

Improving FR901379 titer through combinatorial metabolic engineering and fed-batch fermentation. A Titers of FR901379, WF11899B, and WF11899C were quantified in MEFC09-JFH in shake-flask cultures. JFH: mutant strains MEFC09-JFH; J: mutant strain MEFC09-J; WT: C. empetri MEFC09. Statistical analysis was performed by using Student’s t test (**p < 0.01; ***p < 0.001). B Titers of FR901379 were quantified in the strains MEFC09, MEFC09-HF, and MEFC09-JFH cultivated in a 5 L bioreactor. C Titers of FR901379 were quantified in the strain MEFC09-JFH in fed-batch cultivation

Scale-up production of FR901379 in the 5 L bioreactor

To evaluate the scale-up potential of FR901379 production, batch experiments were carried out in a 5 L bioreactor using engineered strains MEFC09-HF and MEFC09-JFH, with MEFC09 as a control. The titers of FR901379 reached 0.9 g/L, 1.4 g/L, and 2.4 g/L in the strains MEFC09, MEFC09-HF, and MEFC09-JFH, respectively (Fig. 7B). This is significantly higher than those in the shake flask fermentation, which demonstrated the potential for production improvement in the stirred-tank bioreactor. The FR901379 productivity of MEFC09-JFH was much higher than that of MEFC09, MEFC09-HF in the batch fermentation (Additional file 1: Fig. S4). In addition, there was almost no increase in FR901379 production of MEFC09-JFH from Day 6, which was observed from Day 8 in other strains (Fig. 7B). In the fermentation medium MKF for the production of FR901379, D-sorbitol is the main carbon source. Further examination of the D-sorbitol concentration in the fermentation culture showed that D-sorbitol was completely depleted from Day 5 (Additional file 1: Fig. S5A). Therefore, fed-batch fermentation was carried out to achieve higher production of FR901379 using strain MEFC09-JFH. The downward trend in productivity has been significantly slowed. And 4.0 g/L of FR901379 was produced on Day 11 after feeding D-sorbitol three times (Fig. 7C), which was the highest production reported to date. To the best of our knowledge, it is substantially higher than the current titer achieved in industrial production .

Materials and methods

Strains and cultural conditions

All fungal strains used or constructed in this study are listed in Table 1. These strains were cultivated on PDA medium (pH 5.6, purchased from BD company) at 25 ℃ for 7 days and used for multiplication of the inoculum. The transformants were selected on PDAS (PDA with 0.8 M D-sorbitol, pH 5.6) supplemented with appropriate antibiotics as needed, such as 100 mg/L of hygromycin B or geneticin, and cultured for 5–7 days at 30 ℃.

Table 1 Strains used in this study

Overexpression of target genes in C. empetri MEFC09

All plasmids used here are listed in Additional file 1: Table S1. All primers used in this study are listed in Additional file 1: Table S2. The DNA fragments of mcfF, mcfH, mcfP, and mcfS were amplified from genomic DNA of C. empetri MEFC09 using respective primer pairs and cloned into vector pXH2-1 at the restriction sites of Pci I and Hind III, resulting in the plasmids pPM-mcfF, pPM-mcfH, pPM-mcfP and pPM-mcfS, respectively (Additional file 1: Fig. S1) [35]. To construct the mcfJ-overexpressing mutant strain, mcfJ was amplified from the genomic DNA of C. empetri MEFC09 using the primers mcfJ-F1/mcfJ-R and cloned into the PU-ZX vector digested with Xba I, resulting in the PU-mcfJ plasmid (Additional file 1: Fig. S1). The mcfJ expression cassette PgpdAt-mcfJ-Tpgk-hph was amplified from plasmid PU-mcfJ using primers PgpdAt-F/hph-R.

All of the expression cassettes were individually introduced into C. empetri MEFC09 through (PEG)-CaCl2-mediated protoplast transformation [34]. Transformants were selected on PDAS plates amended with 100 mg/L hygromycin B and verified by genomic PCR. To construct the mutant strain MEFC09-HF, the expression cassette PgpdAt-mcfF-TtrpC was fused with marker neo from pPM-4 by fusion PCR and introduced into MEFC09-H. Similarly, the expression cassettes PgpdAt-mcfF-TtrpC-neo and PgpdAt-mcfH-TtrpC-neo were cointroduced into MEFC09-J, resulting in the engineered strain MEFC09-JFH.

Identification of β-1,3-glucan synthase

The β-1,3-glucan synthase coding genes (CEfks1 and CEfks2) were searched in the genome of C. empetri MEFC09 with the sequences of prfks1n and prfks1a from Pezicula radicicola NRRL 12192 as probes [31]. The putative function of the predicted enzymes was confirmed with the online NCBI BLASTP programmer ( Gene disruption was carried out via homologous recombination as described previously [34]. To knock out the CEfks1 gene, approximately 1.2 kb of 5' and 3' DNA of the CEfks1 gene were amplified by PCR from the genome of C. empetri MEFC09 using the primer pairs UCEfks1-F/UCEfks1-R and DCEfks1-F/DCEfks1-R and were fused with the marker hph by fusion PCR. The gene-targeting cassette was amplified using nest primers and introduced into MEFC09-∆ku80 by (PEG)-CaCl2-mediated protoplast transformation. The mutant strains were verified using the primers UCEfks1-F/DCEfks1-R. A similar strategy was used for the deletion of CEfks2. The CEfks2-overexpressing strain was constructed as described above.

Fermentation and HPLC analysis

For the fermentation of all C. empetri strains, the fresh mycelia were crushed and inoculated in 50 mL of seed medium MKS (soluble starch 15 g/L, sucrose 10 g/L, cottonseed meal 5 g/L, peptone 10 g/L, KH2PO4 1 g/L, and CaCO3 2 g/L; pH 6.5) in 250 mL shake flasks for 2 days at 25 °C and 220 rpm [34]. Then, 5 mL of seed culture was inoculated into 50 mL of fermentation medium MKF (glucose 10 g/L, corn starch 30 g/L, peptone 10 g/L, D-sorbitol 160 g/L, (NH4)2SO4 6 g/L, KH2PO4 1 g/L, FeSO4·7H2O 0.3 g/L, ZnSO4·7H2O 0.01 g/L, and CaCO3 2 g/L; pH 6.5) and cultivated at 25 °C and 220 rpm for 8 days. The cultivation broth of C. empetri MEFC09 and the derived engineered strains was analyzed after cultivated for 8 days. Four-fold volume of methanol was added in each sample and shaken on the vortex oscillator at 2600 rpm for 1 h at room temperature. Three independent experiments were performed for each transformant.

The samples were analyzed by HPLC equipped with a reverse-phase C18 column (Agilent, 4.6 × 150 mm, 5 µm) monitored at 210 nm. For HPLC analysis, solvent A was deionized water with 0.05% trifluoroacetic acid and solvent B was acetonitrile with 0.05% trifluoroacetic acid. The following gradient was used at a flow rate of 1 mL/min: 5%-40% solvent B for 3 min, 40%-60% solvent B for 15 min, 100% solvent B for 5 min, and 5% solvent B for 3 min [34]. The amount of FR901379 was quantified based on the peak area.

Sample preparation for scanning electron microscopy

Sample preparation for SEM was performed according to the method reported previously with modification [36]. The fresh mycelia were collected by centrifugation and washed with phosphate buffer solution (PBS, pH 7.4) three times. The samples were fixed in 2.5% glutaraldehyde fixative for at least 1 h and washed with PBS three times for 10 min each time. Osmium tetroxide was added to the samples for 10 min, then they were washed in PBS three times. The samples were dehydrated with 30%, 50%, 70%, 90%, and 100% ethanol for 5 min each. Next, tertiary butanol was added to the samples for 15 min, and the samples were dried in a freezer dryer and loaded onto specimen stubs. They were coated with gold–palladium before observation under a Hitachi S-4800 SEM Cold Field Emission Microscope (Japan).

RNA isolation and transcript quantification

Mycelia were collected from the MKF cultures for 2 days and immediately frozen in liquid nitrogen. Total RNA was isolated using a Takara MiniBEST Universal RNA Extraction Kit (Takara, Japan) according to the manufacturer’s protocol. RNA samples were treated with RNase-free DNase I (Takara, Japan) for 15 min to eliminate the genomic DNA. First strand cDNA was synthesized with the PrimeScript™ RT Reagent Kit with gRNA Eraser (Takara, Japan). All of the primers used for RT‒PCR are listed in Additional file 1: Table S2, with the actin gene used as a reference.

The expression profiles of target genes responsible for the biosynthesis of FR901379 of C. empetri MEFC09, MEFC09-∆mcfJ, and MEFC09-J were compared by RNA sequencing performed by GENEWIZ (Suzhou, China). Then, the corresponding expression levels were obtained by calculating FPKM. The results were illustrated using TBtools based on Euclidean distance calculation [37].

Cultivation in a stirred-tank bioreactor

For batch fermentation, strains MEFC09, MEFC09-HF, and MEFC09-JFH were cultivated in a 5 L stirred-tank bioreactor containing 3 L of MKF medium. Seed cultures of engineered strains were prepared as described above, then 10% (v/v) seed culture was inoculated into the bioreactor and cultivated at 25 °C for 9 days. The aeration was kept at 1.0 vvm (volume of air under standard conditions/volume of liquid/minute) and the dissolved oxygen (DO) level was controlled at 10% air saturation with an automated cascade to control the stirring rate within a 400–600 rpm range. For fed-batch cultivation, the engineered strain MEFC09-JFH was cultivated for 12 days. After 5 days of incubation, an additional 180 g of D-sorbitol was added to the bioreactor on Day 5, Day 6, and Day 8, respectively. Samples were taken every day for HPLC analysis at the same time each day.

Availability of data and materials

All data generated and analyzed during this study were included in this manuscript and the additional files.



Biosynthetic gene clusters


Cytochrome P450


High performance liquid chromatography

PgpdAt :

Promoter of glyceraldehyde-3-phosphate dehydrogenase gene


Potato dextrose agar


Sample preparation for scanning electron microscopyreverse


Transcription-polymerase chain reaction


Phosphate buffer solution


Fragments Per Kilobase of exon model per Million mapped fragments


  1. Denning DW. Echinocandin antifungal drugs. Lancet. 2003;362:1142–51.

    Article  CAS  PubMed  Google Scholar 

  2. Emri T, Majoros L, Tóth V, Pócsi I. Echinocandins: production and applications. Appl Microbiol Biotechnol. 2013;97:3267–84.

    Article  CAS  PubMed  Google Scholar 

  3. Szymański M, Chmielewska S, Czyżewska U, Malinowska M, Tylicki A. Echinocandins—structure, mechanism of action and use in antifungal therapy. J Enzyme Inhib Med Chem. 2022;37:876–94.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Balkovec JM, Hughes DL, Masurekar PS, Sable CA, Schwartz RE, Singh SB. Discovery and development of first in class antifungal caspofungin (CANCIDAS®)—a case study. Nat Prod Rep. 2014;31:15–34.

    Article  CAS  PubMed  Google Scholar 

  5. Carver PL. Micafungin. Ann Pharmacother. 2004;38:1707–21.

    Article  CAS  PubMed  Google Scholar 

  6. Gobernado M, Cantón E. Anidulafungin. Rev Esp Quimioter. 2008;21:99–114.

    CAS  PubMed  Google Scholar 

  7. Cândido ES, Affonseca F, Cardoso MH, Franco OL. Echinocandins as biotechnological tools for treating Candida auris infections. J Fungi (Basel). 2020;6:185.

    Article  PubMed  Google Scholar 

  8. Hüttel W. Echinocandins: structural diversity, biosynthesis, and development of antimycotics. Appl Microbiol Biotechnol. 2021;105:55–66.

    Article  PubMed  Google Scholar 

  9. Aruanno M, Glampedakis E, Lamoth F. Echinocandins for the treatment of invasive Aspergillosis: from laboratory to bedside. Antimicrob Agents Chemother. 2019;63:e00399-e419.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Hashimoto S. Micafungin: a sulfated echinocandin. J Antibiot (Tokyo). 2009;62:27–35.

    Article  CAS  PubMed  Google Scholar 

  11. Iwamoto T, Fujie A, Sakamoto K, Tsurumi Y, Shigematsu N, Yamashita M, Hashimoto S, Okuhara M, Kohsaka M. WF11899A, B and C, novel antifungal lipopeptides. I. Taxonomy, fermentation, isolation and physico-chemical properties. J Antibiot (Tokyo). 1994;47:1084–91.

    Article  CAS  PubMed  Google Scholar 

  12. Chandrasekar PH, Sobel JD. Micafungin: a new echinocandin. Clin Infect Dis. 2006;42:1171–8.

    Article  CAS  PubMed  Google Scholar 

  13. Tomishima M, Ohki H, Yamada A, Maki K, Ikeda F. Novel echinocandin antifungals. Part 1: novel side-chain analogs of the natural product FR901379. Bioorg Med Chem Lett. 2008;18:1474–7.

    Article  CAS  PubMed  Google Scholar 

  14. Tomishima M, Ohki H, Yamada A, Maki K, Ikeda F. Novel echinocandin antifungals. Part 2: optimization of the side chain of the natural product FR901379. Discovery of micafungin. Bioorg Med Chem Lett. 2008;18:2886–90.

    Article  CAS  PubMed  Google Scholar 

  15. Kanda M, Tsuboi M, Sakamoto K, Shimizu S, Yamashita M, Honda H. Improvement of FR901379 production by mutant selection and medium optimization. J Biosci Bioeng. 2009;107:530–4.

    Article  CAS  PubMed  Google Scholar 

  16. Kanda M, Yamamoto E, Hayashi A, Yabutani T, Yamashita M, Honda H. Scale-up fermentation of echinocandin type antibiotic FR901379. J Biosci Bioeng. 2010;109:138–44.

    Article  CAS  PubMed  Google Scholar 

  17. Kim GB, Kim WJ, Kim HU, Lee SY. Machine learning applications in systems metabolic engineering. Curr Opin Biotechnol. 2020;64:1–9.

    Article  CAS  PubMed  Google Scholar 

  18. Wu Q, Zhi Y, Xu Y. Systematically engineering the biosynthesis of a green biosurfactant surfactin by Bacillus subtilis 168. Metab Eng. 2019;52:87–97.

    Article  CAS  PubMed  Google Scholar 

  19. Xu S, Zhang L, Zhou S, Deng Y. Biosensor-based multigene pathway optimization for enhancing the production of glycolate. Appl Environ Microbiol. 2021;87: e0011321.

    Article  PubMed  Google Scholar 

  20. Min T, Xiong L, Liang Y, Xu R, Fa C, Yang S, Hu H. Disruption of stcA blocks sterigmatocystin biosynthesis and improves echinocandin B production in Aspergillus delacroxii. World J Microbiol Biotechnol. 2019;35:109.

    Article  PubMed  Google Scholar 

  21. Ida K, Ishii J, Matsuda F, Kondo T, Kondo A. Eliminating the isoleucine biosynthetic pathway to reduce competitive carbon outflow during isobutanol production by Saccharomyces cerevisiae. Microb Cell Fact. 2015;14:62.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Tong T, Chen X, Hu G, Wang XL, Liu GQ, Liu L. Engineering microbial metabolic energy homeostasis for improved bioproduction. Biotechnol Adv. 2021;53: 107841.

    Article  CAS  PubMed  Google Scholar 

  23. Barquera B, Häse CC, Gennis RB. Expression and mutagenesis of the NqrC subunit of the NQR respiratory Na(+) pump from Vibrio cholerae with covalently attached FMN. FEBS Lett. 2001;492:45–9.

    Article  CAS  PubMed  Google Scholar 

  24. Chen L, Yue Q, Li Y, Niu X, Xiang M, Wang W, Bills GF, Liu X, An Z. Engineering of Glarea lozoyensis for exclusive production of the pneumocandin B0 precursor of the antifungal drug caspofungin acetate. Appl Environ Microbiol. 2015;81:1550–8.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Wei TY, Wu YJ, Xie QP, Tang JW, Yu ZT, Yang SB, Chen SX. CRISPR/Cas9-based genome editing in the filamentous fungus Glarea lozoyensis and its application in manipulating gloF. ACS Synth Biol. 2020;9:1968–77.

    Article  CAS  PubMed  Google Scholar 

  26. Wei TY, Zheng Y, Wan M, Yang S, Tang J, Wu Y, Li J, Chen SX. Analysis of FR901379 biosynthetic genes in Coleophoma empetri by clustered regularly interspaced short palindromic repeats/Cas9-based genomic manipulation. ACS Chem Biol. 2022;17:2130–41.

    Article  CAS  PubMed  Google Scholar 

  27. Men P, Geng C, Zhang X, Zhang W, Xie L, Feng D, Du S, Wang M, Huang X, Lu X. Biosynthesis mechanism, genome mining and artificial construction of echinocandin O-sulfonation. Metab Eng. 2022;74:160–7.

    Article  CAS  PubMed  Google Scholar 

  28. Hüttel W. Structural diversity in echinocandin biosynthesis: the impact of oxidation steps and approaches toward an evolutionary explanation. Z Naturforsch C J Biosci. 2017;72:1–20.

    Article  PubMed  Google Scholar 

  29. Almabruk KH, Dinh LK, Philmus B. Self-resistance of natural product producers: past, present, and future focusing on self-resistant protein variants. ACS Chem Biol. 2018;13:1426–37.

    Article  CAS  PubMed  Google Scholar 

  30. Malla S, Niraula NP, Liou K, Sohng JK. Self-resistance mechanism in Streptomyces peucetius: overexpression of drrA, drrB and drrC for doxorubicin enhancement. Microbiol Res. 2010;165:259–67.

    Article  CAS  PubMed  Google Scholar 

  31. Yue Q, Li Y, Chen L, Zhang X, Liu X, An Z, Bills GF. Genomics-driven discovery of a novel self-resistance mechanism in the echinocandin-producing fungus Pezicula radicicola. Environ Microbiol. 2018;20:3154–67.

    Article  CAS  PubMed  Google Scholar 

  32. Li Z, Li S, Du L, Zhang X, Jiang Y, Liu W, Zhang W, Li S. Engineering bafilomycin high-producers by manipulating regulatory and biosynthetic genes in the marine bacterium Streptomyces lohii. Mar Drugs. 2021;19:29.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Huang X, Tang S, Zheng L, Teng Y, Yang Y, Zhu J, Lu X. Construction of an efficient and robust Aspergillus terreus cell factory for monacolin J production. ACS Synth Biol. 2019;8:818–25.

    Article  CAS  PubMed  Google Scholar 

  34. Men P, Wang M, Li J, Geng C, Huang X, Lu X. Establishing an efficient genetic manipulation system for sulfated echinocandin producing fungus Coleophoma empetri. Front Microbiol. 2021;12: 734780.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Huang X, Lu X, Li JJ. Cloning, characterization and application of a glyceraldehyde-3-phosphate dehydrogenase promoter from Aspergillus terreus. J Ind Microbiol Biotechnol. 2014;41:585–92.

    Article  CAS  PubMed  Google Scholar 

  36. Chan DYL, Li TC. Comparison of the external physical damages between laser-assisted and mechanical immobilized human sperm using scanning electronic microscopy. PLoS ONE. 2017;12: e0188504.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Chen C, Chen H, Zhang Y, Thomas HR, Frank MH, He Y, Xia R. TBtools: An integrative toolkit developed for interactive analyses of big biological data. Mol Plant. 2020;13:1194–202.

    Article  CAS  PubMed  Google Scholar 

Download references


Not applicable.


This research was supported by National Key R&D Program of China (No. 2021YFC2102600), the National Natural Science Foundation of China (U2032139, 32170098), Key R&D Program of Shandong Province (No. 2021ZDSYS02). X.L. and X.H. are supported by the Shandong Taishan Scholarship.

Author information

Authors and Affiliations



XL and XH conceived the project; XL, XH, and PM designed the research; The fungal genetic experiments were carried out by PM, LX, XZ, and WZ; The fermentation experiments were performed by PM and YZ; PM, XH, and XL wrote the manuscript. All authors read and approved the manuscript.

Corresponding authors

Correspondence to Xuenian Huang or Xuefeng Lu.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Table S1.

Plasmids used in this study. Table S2. Primers used in this study. Table S3. The expression profiles of C. empetri MEFC09 and mutant strains. Figure S1. Plasmid maps and cassettes of mcfF (A, G), mcfH (B, G), mcfP (C), mcfS (D), and mcfJ (E), and CEfks2 (F). Figure S2. Titers of FR901379 were quantified in the mutant strains MEFC09-P and MEFC09-S. Figure S3. Functional identification of gene mcfJ. Figure S4. The concentration of D-sorbitol of batch fermentation (A) and fed-batch fermentation (B) in a 5 L bioreactor.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Men, P., Zhou, Y., Xie, L. et al. Improving the production of the micafungin precursor FR901379 in an industrial production strain. Microb Cell Fact 22, 44 (2023).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: